Clodronic acid

Drug Profile

Clodronic acid

Alternative Names: 177501; Ascredar; Bonefos; Bonephos; CL-I.A.; Cl2MDP; Clasteon; Clastoban; Climaclod; Clodeosten; Clodron; Clodron beta; Clodronate; Clodronate disodium; Clody; Difosfonal; Dolkin; Hemocalcin; KCO 692; Lodronat; Loron; Lytos; Mebonat; Moticlod; Nikclod; Ossiten; Ostac; Osteonorm; Osteostab; Sindronat; ZK 00091106

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Schering Oy
  • Developer Abiogen Pharma; Bayer HealthCare Pharmaceuticals; Roche; Schering Oy
  • Class Antihypercalcaemics; Antirheumatics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Collagen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases; Malignant hypercalcaemia; Postmenopausal osteoporosis
  • Phase III Osteoarthritis

Most Recent Events

  • 01 Sep 2015 No recent reports on development identified - Phase-III for Bone metastases in USA (PO)
  • 31 Mar 2013 Chiesi Farmaceutici completes a phase III trial in Postmenopausal osteoporosis (alternative intramuscular formulation) in Italy (NCT01348243)
  • 31 Dec 2012 National Surgical Adjuvant Breast and Bowel Project completes a phase III trial in Bone metastases in USA (B-34; NCT00009945)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top